Timothy Reid
Overview
Explore the profile of Timothy Reid including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
62
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Reid T
J Fam Pract
. 2022 Aug;
71(6 Suppl):S40-S45.
PMID: 35960949
The increasing prevalence of type 1 diabetes (T1D) suggests family physicians will regularly see first-degree relatives of patients with T1D with the genetic propensity for developing T1D. T1D autoantibody screening...
2.
Wright Jr E, Malone D, Trujillo J, Gill J, Huse S, Li X, et al.
J Manag Care Spec Pharm
. 2022 Mar;
28(6):592-603.
PMID: 35352995
People with type 2 diabetes (T2D) who change their basal insulin (BI) may have variable persistence with therapy. Compared with first-generation (long-acting) BI analogs (insulin glargine 100U/mL [Gla-100]; insulin detemir...
3.
Reid T
J Fam Pract
. 2021 Aug;
70(6S):S1-S6.
PMID: 34432617
At the end of the activity, participants will be able to: • Identify how heart failure (HF), chronic kidney disease (CKD), and type 2 diabetes mellitus (T2DM) and associated cardiovascular...
4.
5.
Dailey G, Reid T, White J, Chao J, Zhou F, Paranjape S, et al.
Endocrinol Diabetes Metab
. 2019 Mar;
1(4):e00035.
PMID: 30815563
Aims: Data from the EDITION 3 randomized study and the Clinformatics claims database were analysed to determine whether insulin glargine 300 U/mL (Gla-300) could provide insulin-naive patients with type 2...
6.
Cavaiola T, Kiriakov Y, Reid T
Clin Ther
. 2019 Jan;
41(2):352-367.
PMID: 30655008
Type 2 diabetes (T2D) is a progressive disease caused by insulin resistance and associated progressive β-cell functional decline, as well as multiple other related metabolic and pathophysiologic changes. Left unchecked,...
7.
Zhou F, Yeaw J, Karkare S, DeKoven M, Berhanu P, Reid T
BMJ Open Diabetes Res Care
. 2019 Jan;
6(1):e000593.
PMID: 30622720
Objective: Treatment adherence and persistence are essential to achieving therapeutic goals in diabetes and may be improved by patient support programs (PSPs). The COACH Program was launched in 2015 with...
8.
Goldman J, Gill J, Horn T, Reid T, Strong J, Polonsky W
Diabetes Ther
. 2018 Sep;
9(5):2143-2153.
PMID: 30218432
Introduction: Persistence with basal insulin therapy can be suboptimal, despite recent improvements in insulin formulations and delivery systems. Patient support programs may help increase adherence. This study evaluated the impact...
9.
DeVries J, Meneghini L, Barnett A, Reid T, Dain M, Landgraf W, et al.
Eur Endocrinol
. 2018 Jun;
10(1):23-30.
PMID: 29872460
A better understanding of hypoglycaemia risk when insulin is used in combination with one or more oral antidiabetes agents may assist in the treatment decision-making process for the clinician and...
10.
Shaefer C, Reid T, Vlajnic A, Zhou R, Digenio A
Endocr Pract
. 2015 Aug;
21(12):1323-32.
PMID: 26307902
Objective: Postprandial hyperglycemia (PPHG) may need addressing when glycemic control cannot be maintained in patients with type 2 diabetes mellitus. We investigated whether glycated hemoglobin A1c (A1c) levels ≥7.0% can...